Skip to content
Search

Latest Stories

Bestway Group thrives amid market changes with 5% rise in revenue

Bestway Group thrives amid market changes with 5% rise in revenue

The acquisition of Lexon has reinforced the Group's presence in the pharmacy sector

Well Pharmacy’s parent company, Bestway Group, announced on Wednesday (20 March) that it recorded a five per cent growth in revenues to £4.74 billion for the year ending June 2023, alongside a pre-tax profit of £420.9 million.


During the year, the company also completed acquisition of Lexon UK Holdings, a leading pharmaceutical wholesaler serving over 3,000 retail pharmacy customers across the UK and Eire.

Furthermore, the Group completed the construction of two cement plants in Pakistan, bringing its total cement manufacturing capacity to 15.3 million tonnes per annum.

Sir Anwar Pervez OBE, founder and chairman of Bestway Group, expressed optimism about the new business year and said: “The Group has continued on its growth trajectory in 2023 and we are confident that our businesses will continue to gain share within their respective markets during 2024."

He added that the Group will continue to maintain organic growth across all its business while also providing them support for strategic investments and acquisitions.

The growth comes amidst global challenging times, highlighting the Group's resilience and adaptability in navigating volatile market conditions.

Lord Choudrey CBE, Group Chief Executive of Bestway Group, elaborated that the environment throughout the year ending June 2023 has remained exceptionally volatile as "the world emerged from the Covid pandemic and came to terms with the macro-economic impact of the Ukraine-Russian conflict including significant global inflation."

"Despite facing these immense challenges and the subsequent turbulence that we have seen across global markets I am pleased that the Group has retained its focus on growth, service and efficiency to support customers during this time and it has shown real resilience enabling the Group to exhibit both growth and stability."

“The results are testament to the agility of our business model which will continue to deliver growth in the year ahead," he added.

Bestway Group's diverse business portfolio includes Bestway Wholesale (the UK’s largest independent food wholesaler), Well Pharmacy (the 2nd largest retail pharmacy chain in the UK), Bestway Cement (Pakistan’s largest cement manufacturer) and United Bank Limited (Pakistan’s 2nd largest private bank).

The addition of Lexon to Bestway Group's portfolio has reinforced its presence in the pharmacy sector, solidifying its position as a key industry player.

Moreover, the Group continued its philanthropic approach throughout the year by donating over £2 million, and supporting various charities.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less